SCHEMBL14916111

SCHEMBL14916111

Cn1c(=O)n(Cc2ccc(F)cc2)c(=O)c2cc(C(=O)c3nc(-c4cccnc4)c4ccccn34)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.44
HDAC6 Q9UBN7 7/20 0.42
MMP13 P45452 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
HDAC1 Q13547 7/20 0.41
HDAC8 Q9BY41 3/20 0.41
HDAC11 Q96DB2 2/20 0.41
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ESR1 P03372 1/20 0.39
RECQL P46063 1/20 0.39
MCL1 Q07820 1/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2B Q13224 2/20 0.39
HIF1A Q16665 2/20 0.39
PARG Q86W56 1/20 0.39
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14916909 0.99 PKM (0.44) PKMHDAC6MMP13SLC22A8HDAC1
SCHEMBL15016914 0.88 MMP13 (0.41) HDAC6MMP13SLC22A8HDAC1HDAC8
SCHEMBL322594 0.88 MMP13 (0.46) HDAC6MMP13SLC22A8HDAC1HDAC8
SCHEMBL19206316 0.87 MMP13 (0.41) PKMHDAC6MMP13SLC22A8HDAC1
SCHEMBL322222 0.86 HDAC1 (0.41) HDAC6MMP13SLC22A8HDAC1HDAC8
SCHEMBL15094050 0.86 PARG (0.36) HDAC6MMP13SLC22A8HDAC1HDAC8
SCHEMBL15016935 0.86 MMP13 (0.41) PKMHDAC6MMP13SLC22A8HDAC1
SCHEMBL15094059 0.85 KDM4E (0.40) PKMHDAC6MMP13SLC22A8HDAC1
SCHEMBL14916199 0.84 MMP13 (0.47) PKMHDAC6MMP13SLC22A8HDAC1
SCHEMBL15093892 0.84 HDAC1 (0.39) HDAC6MMP13SLC22A8HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US claimed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP claimed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP claimed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US claimed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US claimed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
EP-2800566-B1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI SA (FR) 2015-10-28 EP disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed
EP-2800566-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2014-11-12 EP disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
WO-2013102860-A1 THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES SANOFI (FR) 2013-07-11 WO disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PKM 97/4885HDAC6 958/4885MMP13 4381/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 PKM 614/4885HDAC6 238/4885MMP13 3718/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PKM 97/4885HDAC6 958/4885MMP13 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.